AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24284609 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine (HCy) levels
Number of subjects: 138
Study 20808114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) program, including psychoeducation and cognitive training, delivered in a group format over a 10-week period, each component lasting 1 hour.
Number of subjects: 41
Study 20808114 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (not receiving the intervention)
Number of subjects: 41
Study 17962204 — intervention group
Group type: EXPERIMENTAL
Intervention: CapOx (capecitabine 1000 mg/m² twice daily on days 1‐14 plus oxaliplatin 130 mg/m² on day 1)
Number of subjects: 190
Study 17962204 — intervention group
Group type: EXPERIMENTAL
Intervention: CapGem (capecitabine 825 mg/m² twice daily on days 1‐14 plus gemcitabine 1000 mg/m² on days 1 and 8)
Number of subjects: 190
Study 17962204 — intervention group
Group type: EXPERIMENTAL
Intervention: mGemOx (gemcitabine 1000 mg/m² on days 1 and 8 plus oxaliplatin 130 mg/m² on day 8)
Number of subjects: 190
Study 16816537 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein as a prognostic marker
Number of subjects: 0
Study 16816537 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin alone or in combination with interleukin-6
Number of subjects: 0
Study 16816537 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 16816537 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical and/or clinical predictive systems
Number of subjects: 0
Study 12942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic dual-arch tray
Number of subjects: 8
Study 12942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal dual-arch tray
Number of subjects: 8
Study 12942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete-arch custom tray
Number of subjects: 8
Study 12942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comfort ranking
Number of subjects: 8
Study 12942055 — intervention group
Group type: COMPARATOR
Intervention: Comparison of die accuracy
Number of subjects: 8
Study 9377610 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 1000 mg QD
Number of subjects: 279
Study 9377610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1500 mg QD
Number of subjects: 279
Study 9377610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 1396427 — intervention group
Group type: EXPERIMENTAL
Intervention: Centromedian thalamic stimulation (on)
Number of subjects: 7
Study 1396427 — intervention group
Group type: COMPARATOR
Intervention: Centromedian thalamic stimulation (off)
Number of subjects: 7
Study 1396427 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label follow-up stimulation (24 h/day)
Number of subjects: 7
Study 3914623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g of ascorbic acid per day
Number of subjects: 41
Study 3914623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 28460137 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean diet (measured by the Literature-based Adherence Score to the Mediterranean Diet - LAMD)
Number of subjects: 3012
Study 28460137 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3012
Study 28221010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (cTnT) level on admission
Number of subjects: 295
Study 28221010 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT level combined with Pneumonia Severity Index (PSI) classification
Number of subjects: 295
Study 26245894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-tympanic dexamethasone
Number of subjects: 30
Study 24228533 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment of traditional Chinese medicine and Western medicine (TCM-WM)
Number of subjects: 164
Study 24228533 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment
Number of subjects: 164
Study 21128114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 606
Study 21128114 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 606
Study 18498883 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine (AE)
Number of subjects: 40
Study 18498883 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine (LE)
Number of subjects: 40
Study 16553541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40-60 mg/day
Number of subjects: 29
Study 16553541 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 29
Study 14977438 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (90 mg total isoflavones/day)
Number of subjects: 38
Study 14977438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10640116 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint protection (JP) education programme
Number of subjects: 35
Study 8961990 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy (40 Gy in 20 fractions of 2 Gy over 4 weeks)
Number of subjects: 469
Study 8961990 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 469
Study 8961990 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy
Number of subjects: 469
Study 1902418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C or Adriamycin, administered endovesically
Number of subjects: 40
Study 1902418 — intervention group
Group type: COMPARATOR
Intervention: Control group (original series)
Number of subjects: 40
Study 1902418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 40
Study 1902418 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravesical recurrences
Number of subjects: 40
Study 6124859 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg bupropion p.o.
Number of subjects: 12
Study 6124859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31273507 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm variables (amplitude, r24, I < O)
Number of subjects: 33
Study 31273507 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm variables (amplitude, r24, IS, IV)
Number of subjects: 33
Study 31273507 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm variable (IV)
Number of subjects: 33
Study 31856964 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0
Study 31856964 — intervention group
Group type: COMPARATOR
Intervention: Infarct-related artery revascularization only
Number of subjects: 0
Study 29356608 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-RIT (CHOP followed by consolidation with iodine-133-Tositumomab radioimmunotherapy)
Number of subjects: 531
Study 29356608 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 531
Study 29356608 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-RIT
Number of subjects: 531
Study 29356608 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 531
Study 26757989 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care testing
Number of subjects: 297
Study 24641985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet laser (fluence of 5 J/cm(2), rate of 6 Hz)
Number of subjects: 27
Study 24641985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet laser
Number of subjects: 27
Study 24641985 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27
Study 24641985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:ytrium-aluminum-garnet laser
Number of subjects: 27
Study 21248779 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid cuff inflation (<1 s)
Number of subjects: 33
Study 21248779 — intervention group
Group type: COMPARATOR
Intervention: Slow cuff inflation (10 s)
Number of subjects: 33
Study 20633873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Breathing (MB)
Number of subjects: 190
Study 20633873 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 190
Study 20633873 — intervention group
Group type: COMPARATOR
Intervention: Loving-Kindness Meditation (LKM)
Number of subjects: 190
Study 17516829 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant IGF-I
Number of subjects: 0
Study 17516829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15738542 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (70 mg/m2 on day 2 or 35 mg/m2 on days 2 and 9 of each 21‐day cycle) and estramustine (280 mg p.o. tid on days 1 through 5 and 8 through 12) plus prednisone (10 mg daily)
Number of subjects: 130
Study 15738542 — intervention group
Group type: COMPARATOR
Intervention: mitoxantrone (12 mg/m2 every 3 weeks) plus prednisone (10 mg daily)
Number of subjects: 130
Study 15738542 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel arms (DEP)
Number of subjects: 130
Study 11943004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-wave insulin administration (70% as a bolus and 30% as a square-wave over 2 h)
Number of subjects: 9
Study 11943004 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-wave insulin administration (over 2 h)
Number of subjects: 9
Study 11943004 — intervention group
Group type: COMPARATOR
Intervention: Single bolus insulin administration
Number of subjects: 9
Study 11943004 — intervention group
Group type: COMPARATOR
Intervention: Double bolus insulin administration (two separate boluses of one-half the same total dose)
Number of subjects: 9
Study 10768034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical columns arrangement of letters (constant horizontal distance)
Number of subjects: 112
Study 10768034 — intervention group
Group type: COMPARATOR
Intervention: Original Bailey-Lovie chart
Number of subjects: 112
Study 7574855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear apple juice
Number of subjects: 12
Study 7574855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloudy apple juice
Number of subjects: 12
Study 7574855 — intervention group
Group type: COMPARATOR
Intervention: Extra clear fluids (excluding fruit juices)
Number of subjects: 12
Study 2200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 306
Study 2200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 306
Study 2200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR
Number of subjects: 306
Study 2200384 — intervention group
Group type: COMPARATOR
Intervention: Control (Stable or forced-dose titration sequence)
Number of subjects: 306
Study 7345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's group treatment of erectile dysfunction with communication and dating skills training; 10 sessions over 6 weeks
Number of subjects: 11
Study 7345158 — intervention group
Group type: COMPARATOR
Intervention: Waiting control period
Number of subjects: 11
Study 7345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's group treatment of erectile dysfunction
Number of subjects: 11
Study 31106728 — intervention group
Group type: EXPERIMENTAL
Intervention: DISCOVER one-day CBT workshop
Number of subjects: 24
Study 31106728 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 31221944 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg BioCell Collagen supplement taken twice daily
Number of subjects: 128
Study 31221944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 28702758 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention (112 messages)
Number of subjects: 411
Study 26369333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) and static stretching (LLLT+Stretch)
Number of subjects: 145
Study 26369333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) placebo and static stretching (LLLTPLACEBO+Stretch)
Number of subjects: 145
Study 26369333 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching alone
Number of subjects: 145
Study 26369333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) alone
Number of subjects: 145
Study 26369333 — intervention group
Group type: COMPARATOR
Intervention: Control group (booklet)
Number of subjects: 145
Study 24158199 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP of 500 pg/mL or greater
Number of subjects: 81
Study 24158199 — intervention group
Group type: EXPERIMENTAL
Intervention: RVEDVI of 140 mL/m or greater
Number of subjects: 81
Study 21190036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 28
Study 21190036 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study 19640922 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg daily for 4 weeks annually)
Number of subjects: 84
Study 19640922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17680183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 : 1 mixture of Lipuro and FA (Lipuro-FA)
Number of subjects: 300
Study 17680183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 : 1 mixture of Dipri and FA (Dipri-FA)
Number of subjects: 300
Study 17680183 — intervention group
Group type: COMPARATOR
Intervention: Plain Lipuro
Number of subjects: 300
Study 17680183 — intervention group
Group type: COMPARATOR
Intervention: Plain Dipri
Number of subjects: 300
Study 12616435 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-to-lateral (M) group
Number of subjects: 67
Study 12616435 — intervention group
Group type: COMPARATOR
Intervention: Lateral-to-medial (L) group
Number of subjects: 67
Study 10979060 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast plus Loratadine (10 mg Montelukast + 20 mg Loratadine)
Number of subjects: 0
Study 10979060 — intervention group
Group type: COMPARATOR
Intervention: Montelukast alone (10 mg)
Number of subjects: 0
Study 8804377 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation, resection, or alcohol injection
Number of subjects: 0
Study 8804377 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for hepatocellular carcinoma
Number of subjects: 0
Study 8804377 — intervention group
Group type: EXPERIMENTAL
Intervention: New imaging techniques (ultrasonographic angiography with CO2 microbubbles, color Doppler ultrasound)
Number of subjects: 0
Study 1428573 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Fluoro‐Uracil (5FU) - 10 injections
Number of subjects: 25
Study 1428573 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin - 1 subconjunctival preoperative injection
Number of subjects: 25
Study 1428573 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Fluoro‐Uracil (5FU)
Number of subjects: 25
Study 1428573 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin
Number of subjects: 25
Study 6428278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn
Number of subjects: 16
Study 6428278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3549476 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus intravenous Corynebacterium parvum (C. parvum)
Number of subjects: 283
Study 3549476 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 283
Study 3549476 — intervention group
Group type: EXPERIMENTAL
Intervention: C. parvum therapy
Number of subjects: 283
Study 30197273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g OM-3CA
Number of subjects: 78
Study 30197273 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 78
Study 30197273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25743238 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone (O2-O3) discolysis with steroid and anesthetic
Number of subjects: 154
Study 25743238 — intervention group
Group type: COMPARATOR
Intervention: Steroid and anesthetic (Control Group)
Number of subjects: 154
Study 23041591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab maintenance therapy following definitive RT with concomitant cetuximab
Number of subjects: 91
Study 23041591 — intervention group
Group type: COMPARATOR
Intervention: Concomitant cetuximab + RT (69.9 Gy) without maintenance
Number of subjects: 91
Study 20630163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Lunch Is In The Bag program)
Number of subjects: 132
Study 20630163 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 132
Study 17851252 — intervention group
Group type: EXPERIMENTAL
Intervention: Coital incontinence group
Number of subjects: 180
Study 16369474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 10
Study 16369474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15314387 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music (20 minutes once a day for 3 days)
Number of subjects: 40
Study 15314387 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 minutes of rest)
Number of subjects: 40
Study 10957827 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intolerance of uncertainty (gambling procedure)
Number of subjects: 42
Study 10957827 — intervention group
Group type: COMPARATOR
Intervention: Decreased intolerance of uncertainty (gambling procedure)
Number of subjects: 42
Study 8781791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (Medimix) in 50% oxygen
Number of subjects: 38
Study 8781791 — intervention group
Group type: COMPARATOR
Intervention: Pethidine hydrochloride 1 mg/kg
Number of subjects: 38
Study 1377311 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 23
Study 1377311 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photoablation
Number of subjects: 23
Study 6143815 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 9
Study 6143815 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 30 mg with Cimetidine 300 mg every 6 h
Number of subjects: 9
Study 31829170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-fast-track anesthesia (UFTA)
Number of subjects: 194
Study 31829170 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia
Number of subjects: 194
Study 30428403 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa followed by hp-hMG
Number of subjects: 234
Study 30428403 — intervention group
Group type: COMPARATOR
Intervention: hp-hMG
Number of subjects: 234
Study 27338674 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction using Ash forceps
Number of subjects: 30
Study 27338674 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty surgery
Number of subjects: 30
Study 23975477 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV prevention intervention
Number of subjects: 0
Study 23975477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22339483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 45-450 μg single intranasal doses
Number of subjects: 10
Study 22339483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 120 μg three times daily for 15 days
Number of subjects: 10
Study 22339483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 120 μg three times daily for 5 days with a final single dose on day 7
Number of subjects: 10
Study 22339483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 45, 90, and 180 μg single intranasal doses
Number of subjects: 10
Study 20483156 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 2784
Study 18028196 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved mechanical oral hygiene
Number of subjects: 106
Study 18028196 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial mouth rinse (amine and stannous fluoride)
Number of subjects: 106
Study 18028196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intensive mechanical and antibacterial measures
Number of subjects: 106
Study 18028196 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific regimen
Number of subjects: 106
Study 16275600 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 ng/mL)
Number of subjects: 15
Study 16275600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16275600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-current-density electrical stimulation
Number of subjects: 15
Study 16275600 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1, 1 ng/mL)
Number of subjects: 15
Study 11972485 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine
Number of subjects: 137
Study 10865160 — intervention group
Group type: EXPERIMENTAL
Intervention: Underage drinking
Number of subjects: 7061
Study 10865160 — intervention group
Group type: EXPERIMENTAL
Intervention: Residence in a fraternity or sorority
Number of subjects: 7061
Study 10865160 — intervention group
Group type: EXPERIMENTAL
Intervention: Very easy access to alcohol
Number of subjects: 7061
Study 10865160 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtaining drinks at lower prices (under $1 each or a set fee for unlimited drinks)
Number of subjects: 7061
Study 10865160 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking beer
Number of subjects: 7061
Study 9036717 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral gold
Number of subjects: 358
Study 1462864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 U glandular kallikrein orally for 5 weeks
Number of subjects: 100
Study 1462864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 U glandular kallikrein orally for 12 weeks
Number of subjects: 100
Study 1462864 — intervention group
Group type: COMPARATOR
Intervention: 1800 U glandular kallikrein orally
Number of subjects: 100
Study 4091992 — intervention group
Group type: EXPERIMENTAL
Intervention: oral solution
Number of subjects: 12
Study 4091992 — intervention group
Group type: COMPARATOR
Intervention: tablet
Number of subjects: 12